Shopping Cart 0
Cart Subtotal
AED 0

BeyondSpring Inc (BYSI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

BeyondSpring Inc (BeyondSpring) is a clinical stage biopharmaceutical company focused on the development of immune-oncology cancer therapies. The company offers lead compound, Plinabulin, is derived from a natural compound which holds a number of biochemical activities and provides multiple potential therapeutic potentials in various types of cancers; BPI-002, an oral small molecule agent used for the treatment of colon cancer; BPI-003 and BPI-004 against various tumors. Its target areas include non-small cell lung cancer, neutropenia prevention, and plinabulin + nivolumab. The company holds a license from the Fred Hutchinson Cancer Research Center and University of Washington for a range of platform technology which concentrates on a novel mechanism to inhibit a various oncogenes. BeyondSpring is headquartered in New York, the US.

BeyondSpring Inc (BYSI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

BeyondSpring Pharma Acquires Rights to Plinabulin from Nereus Pharma 11

Venture Financing 12

BeyondSpring Pharma Raises USD20 Million in Series A Financing 12

Private Equity 13

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 13

Partnerships 14

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

Equity Offering 15

BeyondSpring to Raise USD20 in Private Placement of Shares 15

BeyondSpring Prices Private Placement of Shares for USD50.8 Million 16

BeyondSpring Prices IPO for USD3.5 Million 18

BeyondSpring Inc-Key Competitors 20

BeyondSpring Inc-Key Employees 21

BeyondSpring Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Jun 21, 2018: BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results 23

Apr 03, 2018: BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results 25

Nov 09, 2017: BeyondSpring Reports Third Quarter 2017 Operational and Financial Results 27

Aug 21, 2017: BeyondSpring Provides Operational Update for Second Quarter of 2017 28

May 22, 2017: BeyondSpring Reports First Quarter 2017 Financial Results 30

Apr 28, 2017: BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results 32

Corporate Communications 35

Aug 01, 2018: Beyondspring appoints Richard J. Daly as chief operating officer to lead the transition to commercialization 35

Mar 27, 2018: BeyondSpring Names Edward Dongheng Liu As Chief Financial Officer 36

Jan 03, 2018: BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member 37

Product News 38

01/10/2017: BeyondSpring to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco 38

Product Approvals 39

Jan 24, 2017: FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia 39

Clinical Trials 40

Feb 21, 2017: BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

BeyondSpring Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Deals By Therapy Area, 2012 to YTD 2018 9

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BeyondSpring Pharma Acquires Rights to Plinabulin from Nereus Pharma 11

BeyondSpring Pharma Raises USD20 Million in Series A Financing 12

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 13

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

BeyondSpring to Raise USD20 in Private Placement of Shares 15

BeyondSpring Prices Private Placement of Shares for USD50.8 Million 16

BeyondSpring Prices IPO for USD3.5 Million 18

BeyondSpring Inc, Key Competitors 20

BeyondSpring Inc, Key Employees 21

BeyondSpring Inc, Subsidiaries 22

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

BeyondSpring Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

BeyondSpring Inc (BeyondSpring) is a clinical stage biopharmaceutical company focused on the development of immune-oncology cancer therapies. The company offers lead compound, Plinabulin, is derived from a natural compound which holds a number of biochemical activities and provides multiple potential therapeutic potentials in various types of cancers; BPI-002, an oral small molecule agent used for the treatment of colon cancer; BPI-003 and BPI-004 against various tumors. Its target areas include non-small cell lung cancer, neutropenia prevention, and plinabulin + nivolumab. The company holds a license from the Fred Hutchinson Cancer Research Center and University of Washington for a range of platform technology which concentrates on a novel mechanism to inhibit a various oncogenes. BeyondSpring is headquartered in New York, the US.

BeyondSpring Inc (BYSI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

BeyondSpring Pharma Acquires Rights to Plinabulin from Nereus Pharma 11

Venture Financing 12

BeyondSpring Pharma Raises USD20 Million in Series A Financing 12

Private Equity 13

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 13

Partnerships 14

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

Equity Offering 15

BeyondSpring to Raise USD20 in Private Placement of Shares 15

BeyondSpring Prices Private Placement of Shares for USD50.8 Million 16

BeyondSpring Prices IPO for USD3.5 Million 18

BeyondSpring Inc-Key Competitors 20

BeyondSpring Inc-Key Employees 21

BeyondSpring Inc-Locations And Subsidiaries 22

Head Office 22

Other Locations & Subsidiaries 22

Recent Developments 23

Financial Announcements 23

Jun 21, 2018: BeyondSpring Provides Operational Updates and First-Quarter 2018 Financial Results 23

Apr 03, 2018: BeyondSpring Provides Operational Update and Fourth-Quarter and Full-Year 2017 Financial Results 25

Nov 09, 2017: BeyondSpring Reports Third Quarter 2017 Operational and Financial Results 27

Aug 21, 2017: BeyondSpring Provides Operational Update for Second Quarter of 2017 28

May 22, 2017: BeyondSpring Reports First Quarter 2017 Financial Results 30

Apr 28, 2017: BeyondSpring Provides Quarterly Operational Update and Full Year 2016 Results 32

Corporate Communications 35

Aug 01, 2018: Beyondspring appoints Richard J. Daly as chief operating officer to lead the transition to commercialization 35

Mar 27, 2018: BeyondSpring Names Edward Dongheng Liu As Chief Financial Officer 36

Jan 03, 2018: BeyondSpring Appoints Life Sciences Veteran Patrick Fabbio to Board of Directors as an Independent Member 37

Product News 38

01/10/2017: BeyondSpring to Present at Biotech Showcase 2017 During Annual JPMorgan Healthcare Conference on January 10 in San Francisco 38

Product Approvals 39

Jan 24, 2017: FDA Accepts BeyondSpring IND Application for Plinabulin for the Prevention of Chemotherapy-Induced Neutropenia 39

Clinical Trials 40

Feb 21, 2017: BeyondSprings Promising Clinical Data for Lead Asset on Non-Small Cell Lung Cancer Treatment Selected for Presentation at 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 40

Appendix 41

Methodology 41

About GlobalData 41

Contact Us 41

Disclaimer 41


List Of Figure

List of Figures

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

BeyondSpring Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

BeyondSpring Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

BeyondSpring Inc, Deals By Therapy Area, 2012 to YTD 2018 9

BeyondSpring Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BeyondSpring Pharma Acquires Rights to Plinabulin from Nereus Pharma 11

BeyondSpring Pharma Raises USD20 Million in Series A Financing 12

BeyondSpring Pharma Raises USD15.3 Million in Equity Financing 13

BeyondSpring Pharma Enters into Agreement with Fred Hutchinson Cancer Research Center 14

BeyondSpring to Raise USD20 in Private Placement of Shares 15

BeyondSpring Prices Private Placement of Shares for USD50.8 Million 16

BeyondSpring Prices IPO for USD3.5 Million 18

BeyondSpring Inc, Key Competitors 20

BeyondSpring Inc, Key Employees 21

BeyondSpring Inc, Subsidiaries 22

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

BeyondSpring Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.